HOME >> BIOLOGY >> NEWS
New strategy for treating allergic disorders

Ghent − Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders. VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX − a spin-off from VIB and Ghent University − is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our bodys own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treat
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Aug-2007


Page: 1 2

Related biology news :

1. Does EPA have an adequate strategy to oversee nanotechnologies?
2. High blood pressure medication strategy proves effective in Hispanic women
3. Rutgers: GM/GMO/Biotech crop containment strategy
4. Scientists identify new strategy for preventing acute and chronic brain disease
5. International risk research strategy and funding needed for nanotech safety
6. Study shows metabolic strategy of stressed cell
7. Trojan horse strategy defeats drug-resistant bacteria
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Drug strategy makes cancer genes get lost in translation
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/13/2018)... ... November 13, 2018 , ... ... systems for controlled-environment cultivation applications. VYPR 2 is well suited for sole-source and ... and ornamental growing markets. , “As an all-purpose light which can be ...
(Date:11/13/2018)... ... November 12, 2018 , ... ... events and webinars, will be hosting its 9th Annual Clinical Diagnostics & ... and treatments available, and updates in regulatory processes to ensure patient safety and ...
(Date:11/13/2018)... ... 13, 2018 , ... Kenall has enhanced the popular MedMaster MAEC Series LED ... linear overbed luminaires are equipped with symmetric ambient and asymmetric exam modes, and an ... Intended to be specified in pairs, the MAEC is 8” x 48” and has ...
Breaking Biology News(10 mins):
(Date:11/7/2018)... ... , ... Since September of this year, stem cell biotechnology ... tissue stem cell counting problem in stem cell medicine and the stem cell ... with new educational publications and presentations at clinical trial supply conferences, at meetings ...
(Date:11/5/2018)... , ... November 05, 2018 , ... ... telemedicine company backed by Siemens Healthineers and several healthcare VC firms announces at ... solution and making a history by purchasing tokens and obtaining its first radiology ...
(Date:11/3/2018)... ... November 01, 2018 , ... Triangle Insights Group, a ... as one of the fastest-growing private companies in the United States, appearing on this ... ranks private companies based on percentage revenue growth over the previous three years. ...
(Date:10/31/2018)... ... October 30, 2018 , ... The assessment of cell health ... of experimental biology. Reproducibility of cell-based assays is one of the key points ... assay type, there are many more factors to be considered to decrease data ...
Breaking Biology Technology:
Cached News: